Connect with us

Technology

Global Exosomes Market to Reach USD 2,250 Million by 2034 at 28.8% CAGR as Expanding Applications in Drug Delivery, Diagnostics, and Regenerative Medicine Fuel Market Growth, Reports Maximize Market Research

Published

1 hour ago

on

PUNE, India, Sept. 22, 2026 /PRNewswire/ — The Global Exosomes Market was valued at USD 230.55 Million in 2025 and is projected to expand at a 28.8% CAGR from 2026 to 2034, reaching USD 2,250 Million by 2034, according to a new analysis by Maximize Market Research.

Global Exosomes Market

The Global Exosomes Market Report 2025 provides a detailed analysis of market trends, growth drivers, emerging technologies, competitive developments, and forecasts through 2034. Exosomes are nanosized extracellular vesicles released by cells that transport proteins, lipids, and genetic material between cells, supporting important biological communication processes. The market includes exosome-based products and technologies used across therapeutics, drug delivery, diagnostics, biomarker research, regenerative medicine, and other biomedical applications.

The growing focus on advanced drug delivery and precision medicine is supporting the development of exosome-based technologies. Increasing research into the biological functions of exosomes, rising investment in biotechnology, and advancements in isolation, characterization, and engineering technologies are encouraging pharmaceutical and biotechnology companies to expand their exosome-related pipelines. Their potential to serve as targeted delivery vehicles for therapeutic molecules is also creating new opportunities across drug development and regenerative medicine.

The expanding use of exosomes in diagnostics and biomarker research is further supporting market development as researchers explore their potential for disease detection and monitoring. Companies and research institutions are increasingly focusing on engineered exosomes, scalable manufacturing, and clinical applications to address the growing demand for advanced cell-free therapeutic solutions. These developments, combined with increasing R&D activity and expanding applications across healthcare and life sciences, are expected to strengthen the global exosomes market landscape.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.maximizemarketresearch.com/request-sample/189733/ 

Global Exosomes Market gains momentum as advanced drug delivery, regenerative medicine, and expanding biotechnology research accelerate innovation: Maximize Market Research unveils key insights.

Global Exosomes Market Size & Forecast:

Parameter

Value

Market Size (Base Year 2025)

USD 230.55 Million

Forecast Market Size (2034)

USD 2,250 Million

CAGR (2026-2034)

28.8 %

Base Year

2025

Forecast Period

2026-2034

Historical Period

2020-2025

Global Exosomes Market Trends & Insights

North America leads the Global Exosomes Market, supported by advanced biotechnology, strong pharmaceutical R&D, and growing clinical research in exosome-based therapeutics and diagnostics.Asia-Pacific is emerging as a high-growth region, driven by increasing biotechnology investment, healthcare expenditure, and research into extracellular vesicle technologies.Exosome-based drug delivery and regenerative medicine are gaining traction due to their potential in targeted therapies, tissue repair, and cell-free treatment approaches.Exosome diagnostics and biomarker research are expanding, particularly for disease detection, monitoring, liquid biopsy, and personalized medicine.Advances in exosome isolation, purification, characterization, and engineering are improving scalability and supporting wider therapeutic and clinical applications.

Advanced Drug Delivery and Therapeutic Applications Drive Market Growth

The expanding use of exosomes in drug delivery, regenerative medicine, diagnostics, and therapeutic development is driving market growth. Increasing biotechnology R&D, clinical research, and investment in exosome-based therapeutics are encouraging pharmaceutical and biotechnology companies to explore exosomes as carriers for drugs, proteins, RNA, and other biomolecules.

High Development Costs and Manufacturing Complexity Restrain Market Growth

High R&D costs, complex exosome isolation and purification processes, manufacturing challenges, and limited standardization can restrict wider commercialization. Variations in exosome quality, characterization methods, scalability, and regulatory requirements also create challenges for companies developing exosome-based products and extracellular vesicle technologies.

Exosome-Based Therapeutics and Diagnostics Create Opportunities

Growing research into engineered exosomes, targeted drug delivery, biomarkers, liquid biopsy, regenerative medicine, and cell-free therapies is creating new market opportunities. Advances in exosome engineering, characterization, and therapeutic development are supporting applications across drug development, disease diagnosis, and personalized medicine.

Standardization and Regulatory Challenges Create Barriers

Limited standardization in exosome isolation, characterization, manufacturing, quality control, and clinical evaluation remains a key challenge. Differences in production methods and regulatory requirements can affect the consistency, safety, and scalability of exosome-based therapeutics and diagnostics, encouraging industry players to develop more reliable and standardized technologies.

Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/request-sample/189733/ 

Global Exosomes Market Segmentation Insights

The Global Exosomes Market is segmented by Product, Application, Indication, and End User. Increasing research into exosome-based therapeutics, drug delivery, diagnostics, regenerative medicine, and biomarker applications, along with advances in extracellular vesicle technologies, is supporting market development across these segments.

Segmentation

Sub-Segments

By Product

Kits & Reagents; Instruments; Services; Others

By Application

Drug Delivery; Diagnostics; Regenerative Medicine; Biomarker Discovery; Others

By Indication

Cancer; Neurological Disorders; Cardiovascular Diseases; Inflammatory & Autoimmune Diseases; Others

By End User

Pharmaceutical & Biotechnology Companies; Hospitals & Clinics; Research & Academic Institutes; Diagnostic Centers; Others

North America Leads the Exosomes Market While Asia Pacific Emerges as a High-Growth Region

North America holds a significant position in the Global Exosomes Market, supported by advanced biotechnology infrastructure, strong pharmaceutical and life sciences R&D, high investment in extracellular vesicle research, and increasing clinical development of exosome-based therapeutics and diagnostics. The United States represents a major market due to its strong biotechnology ecosystem and expanding applications of exosomes in drug delivery, biomarker discovery, regenerative medicine, and personalized medicine. Canada also contributes through increasing biomedical research and adoption of advanced life sciences technologies.

Europe represents an important market, supported by established healthcare and biotechnology infrastructure, research funding, and growing interest in exosome isolation, characterization, engineering, and therapeutic applications. Germany, the United Kingdom, France, Italy, and Spain are key contributors, with pharmaceutical companies and research institutions advancing extracellular vesicle technologies, diagnostics, drug delivery, and regenerative medicine.

Asia Pacific is expected to witness strong growth as biotechnology capabilities expand and investment in life sciences, cell-free therapies, and advanced drug delivery technologies increases. China, Japan, India, South Korea, and Australia are important markets, supported by expanding pharmaceutical R&D, increasing healthcare expenditure, and growing research into exosome-based therapeutics, diagnostics, biomarker research, and regenerative medicine.

Middle East & Africa is gradually developing as investments in healthcare infrastructure, biotechnology research, and advanced diagnostic technologies increase. The UAE, Saudi Arabia, Israel, and South Africa are contributing through growing interest in precision medicine, molecular diagnostics, regenerative medicine, and emerging extracellular vesicle applications.

South America is supported by improving healthcare infrastructure, expanding biotechnology research, and increasing adoption of advanced diagnostic and therapeutic technologies. Brazil represents an important regional market, while Argentina, Chile, and Colombia are contributing as research capabilities and access to innovative biomedical and exosome-based technologies continue to develop.

Leading Companies Strengthen the Exosomes Technology and Therapeutics Landscape

Thermo Fisher Scientific Inc., Danaher Corporation, Sartorius AG, Lonza Group Ltd., and System Biosciences, LLC are among the prominent companies contributing to the exosome and extracellular vesicle technology landscape. Their activities across exosome isolation, purification, characterization, research tools, and bioprocessing solutions are supporting advancements in exosome research and commercialization. The market is also attracting biotechnology companies focused on engineered exosomes, targeted drug delivery, regenerative medicine, and exosome-based therapeutics.

Global Exosomes Market Competitive Landscape

The Global Exosomes Market is highly research-oriented and technology-driven, with companies focusing on exosome isolation and purification technologies, characterization platforms, engineered exosomes, drug delivery systems, biomarker discovery, diagnostics, regenerative medicine, and therapeutic development. Key players include Thermo Fisher Scientific Inc., Danaher Corporation, Sartorius AG, Lonza Group Ltd., System Biosciences, LLC, QIAGEN N.V., Bio-Techne Corporation, and NanoView Biosciences, Inc., alongside emerging biotechnology companies specializing in extracellular vesicle applications. Competition is shaped by R&D investment, technology innovation, product development, strategic collaborations, clinical research, manufacturing capabilities, and expansion into therapeutic and diagnostic applications.

Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/checkout/189733/ 

Exosomes Market, Key Players:

Thermo Fisher Scientific Inc.Danaher Beckman CoulterQIAGEN N.V.Lonza Group Ltd.Hitachi Chemical Co., Ltd.Merck KGaASistemic Ltd.System Biosciences, LLCBio-Techne CorporationAMS Biotechnology Ltd.NanoFCMNX Prenatal Inc.ReNeuron Group plcCapricor Therapeutics, Inc.Evox Therapeutics Ltd.Codiak Biosciences, Inc.Exosome Diagnostics, Inc.Malvern Panalytical Ltd.Miltenyi Biotec GmbHNorgen Biotek Corp.Aethlon Medical, Inc.Aruna BioHansaBioMed Life Sciences Ltd.Capricor Therapeutics, Inc.Unicyte AGOthers

Frequently Asked Questions:

1] What segments are covered in the Exosomes Market report?
Ans. The segments covered in the Exosomes Market report are based on product, application, indication, end user, and region.

2] Which region is expected to hold the highest share in the Exosomes Market?
Ans. North America is expected to hold the highest share in the Exosomes Market during the forecast period.

3] What is the market size of the Exosomes Market by 2034?
Ans. The Exosomes Market is expected to reach approximately USD 2,250 Million by 2034.

4] What is the forecast period for the Exosomes Market?
Ans. The forecast period for the Exosomes Market is 2026–2034.

5] What was the market size of the Exosomes Market in 2025?
Ans. The Exosomes Market was valued at approximately USD 230.55 Million in 2025.

Access Full Summary: https://www.maximizemarketresearch.com/market-report/exosomes-market/189733/ 

Analyst Perspective

Analysts highlight that the Global Exosomes Market is being shaped by increasing R&D activity in extracellular vesicle technologies, growing applications in drug delivery, diagnostics, regenerative medicine, and rising investment in biotechnology. Advances in exosome isolation, purification, characterization, and engineering are supporting the development of innovative exosome-based therapeutics and cell-free treatment approaches. At the same time, high development costs, manufacturing complexity, limited standardization, scalability issues, and regulatory requirements remain important challenges. The increasing focus on engineered exosomes, targeted drug delivery, biomarker discovery, precision medicine, and regenerative therapies is creating new opportunities for pharmaceutical, biotechnology, and research organizations.

Related Reports:

Biomarkers Market

Single Cell Analysis Market

Cancer Biomarkers Market

Molecular Diagnostics Market

Stem Cell Therapy Market

About Maximize Market Research – Global Exosomes Market

Maximize Market Research is a leading global market research and business consulting firm delivering actionable insights across the Healthcare and Life Sciences sector, including the Global Exosomes Market. Our data-driven, growth-focused research helps businesses understand evolving market trends, assess market dynamics, identify emerging opportunities, and evaluate developments across exosome-based therapeutics, drug delivery, diagnostics, regenerative medicine, biomarker research, and extracellular vesicle technologies.

Expertise in Exosomes & Extracellular Vesicle Research

With strong expertise in healthcare, biotechnology, and pharmaceutical market research, Maximize Market Research helps industry stakeholders understand exosome market trends, technological developments, competitive activity, R&D investments, and emerging applications. Our insights support informed decisions across exosome isolation, purification, characterization, engineering, drug delivery systems, diagnostics, regenerative medicine, biomarker discovery, and exosome-based therapeutic development, helping businesses identify opportunities across the global exosomes market.

Contact:
Lumawant Godage
MAXIMIZE MARKET RESEARCH PVT. LTD.
+91 96073 65656
Email: sales@maximizemarketresearch.com   
Content Source: https://www.maximizemarketresearch.com/market-report/exosomes-market/189733/
Visit Our Web Site: https://www.maximizemarketresearch.com/   
LinkedIn.com: https://www.linkedin.com/company/maxmize-market-research-pvt-ltd/
Instagram: https://www.instagram.com/maximizemarketresearch/
Facebook: https://www.facebook.com/maximizemarketresearch/   
X (Twitter): https://x.com/MMRAnalytics

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/global-exosomes-market-to-reach-usd-2-250-million-by-2034-at-28-8-cagr-as-expanding-applications-in-drug-delivery-diagnostics-and-regenerative-medicine-fuel-market-growth-reports-maximize-market-research-302886322.html

SOURCE Maximize Market Research Pvt. Ltd.

Related Topics:
Continue Reading

Technology

Nuveen Prices Senior Notes Offerings

Published

50 seconds ago

on

September 22, 2026

By

NEW YORK, Sept. 22, 2026 /PRNewswire/ — Nuveen, LLC (“Nuveen”) announced today the pricing of (1) an offering (the “GBP Offering”) of £550 million aggregate principal amount of 6.052% Senior Notes due 2031 (the “2031 GBP Notes”), and (2) an offering (the “USD Offering”) of $2 billion aggregate principal amount of Senior Notes which were offered in three series: (i) a series of 5.572% Senior Notes due 2029 in an aggregate principal amount of $750 million (the “2029 USD Notes”), (ii) a series of 5.738% Senior Notes due 2031 in an aggregate principal amount of $750 million (the “2031 USD Notes”) and (iii) a series of 6.063% Senior Notes due 2036 in an aggregate principal amount of $500 million (the “2036 USD Notes” and, together with the 2031 GBP Notes, the 2029 USD Notes and the 2031 USD Notes, the “Notes”).

Nuveen intends to use the net proceeds for general corporate purposes, which may include, among other things, to fund a portion of the cash consideration for Nuveen’s acquisition (the “Acquisition”) of Schroders plc and to pay fees and expenses related to the Acquisition and to this offering.

The Notes will be unsecured, senior obligations of Nuveen. The 2031 GBP Notes will mature on September 25, 2031, the 2029 USD Notes will mature on September 25, 2029, the 2031 USD Notes will mature on September 25, 2031 and the 2036 USD Notes will mature on September 25, 2036.

The closing of the GBP Offering is not contingent on the closing of the USD Offering, nor is the closing of the USD Offering contingent on the closing of GBP Offering.

The Notes were offered only to (i) persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and (ii) certain non-U.S. persons outside the United States pursuant to Regulation S under the Securities Act. The Notes have not been registered under the Securities Act or any state securities laws and therefore may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

About Nuveen

Nuveen, a TIAA Company, is a global investment leader, managing $1.4 trillion in public and private assets for clients around the world, as of June 30, 2026. With broad expertise across income and alternatives, we invest in the growth of businesses, real estate, infrastructure, and natural capital, providing clients with the reliability, access, and foresight unique to our 125+ year heritage. Our prevailing perspective on the future drives our ambition to innovate and adapt our business to the changing needs of investors — all to pursue lasting performance for our clients, our communities, and our global economy.

Forward-Looking Statements

This press release contains certain statements that may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical or present facts or conditions, included herein are “forward-looking statements.” Included among “forward- looking statements” are, among other things, statements regarding Nuveen’s business strategy, plans and objectives, including the use of proceeds from the offering. Though Nuveen believes that the expectations reflected in these “forward-looking statements” are reasonable, they are inherently uncertain and involve a number of risks and uncertainties beyond Nuveen’s control. In addition, assumptions may prove to be inaccurate. Actual results may differ materially from those anticipated or implied in “forward-looking statements” as a result of a variety of factors. These “forward-looking statements” speak only as of the date made, and other than as required by law, Nuveen undertakes no obligation to update or revise any “forward-looking statement” or provide reasons why actual results may differ, whether as a result of new information, future events or otherwise.

Media Contact
Sally Lyden | Sally.Lyden@nuveen.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuveen-prices-senior-notes-offerings-302886799.html

SOURCE Nuveen

Continue Reading

Technology

UTulsa rises to Top 75 private research university in U.S. News rankings

Published

51 seconds ago

on

September 22, 2026

By

TULSA, Okla., Sept. 22, 2026 /PRNewswire/ — The University of Tulsa is ranked a Top 75 private research university, according to the 2027 U.S. News & World Report’s Best College report released Tuesday. The publication also ranks UTulsa the No. 1 best value for higher education in the state of Oklahoma.

Academic excellence and outstanding outcomes drive UTulsa’s recognition as a leading small, private research university.

UTulsa advanced 10 places in overall rank for national universities, increased 16 spots in undergraduate engineering programs, jumped 57 positions in undergraduate computer science programs, climbed 26 places in undergraduate business programs and rose eight spots among the best colleges for veterans.

The University of Tulsa remained No. 3 for undergraduate petroleum engineering programs among all national universities and No. 1 in Oklahoma.

Earlier this year, UTulsa took the bold step to increase access to academic excellence by announcing that the annual undergraduate rate for tuition and required fees will be set at $25,000 beginning in fall 2027. Additionally, new undergraduates will have that rate locked in for at least four years. And once students factor in merit- and need-based financial aid, most will pay even less than the published cost. This move makes The University of Tulsa the most affordable private research university in the nation’s heartland.

U.S. News collected data for the 2027 report before UTulsa made its tuition announcement, signaling that future best value rankings will continue an upward trajectory once the new pricing structure is fully considered.

Tuesday’s rankings news is just the latest of many accolades UTulsa has acquired this year, including:

Named No. 11 in the country for best student experience by the Wall Street JournalRated the top university in Oklahoma by WalletHubRecognized by Money magazine for highest median income for recent grads in Oklahoma

According to Niche.com, students who receive a bachelor’s degree from The University of Tulsa report a median starting salary of $58,279.

“While student experience and post-graduation outcomes will always be our primary focus, these and other rankings confirm that we are a university on the rise. We are on the right track and poised for growth and more significant impact in the near and long term,” said President Stacy Leeds. “Today’s announcement highlights the outstanding achievements of our students, the dedication of our faculty and staff and the generosity of donors who provide opportunity at every turn.”

View original content to download multimedia:https://www.prnewswire.com/news-releases/utulsa-rises-to-top-75-private-research-university-in-us-news-rankings-302886814.html

SOURCE The University of Tulsa

Continue Reading

Technology

Streem Welcomes Back Tess Fezzuoglio as Commercial Director to Lead Next Phase of Growth

Published

53 seconds ago

on

September 22, 2026

By

SYDNEY, Sept. 23, 2026 /PRNewswire/ — Streem is pleased to announce the return of Tess Fezzuoglio, who rejoins the business as Commercial Director to lead the next phase of commercial growth.

Having previously been part of Streem’s early growth from 2020 to 2022, Fezzuoglio returns to Streem armed with international experience, a fresh perspective and a deep understanding of the industry to continue Streem’s expansion.

Tess brings over 11 years of experience in the media intelligence industry, having spent the last 4 years in London at Onclusive, leading Northern Europe’s commercial arm.

In her new role, Fezzuoglio will oversee Streem’s commercial operations and client strategy, continuing to drive expansion across corporate, government, and agency sectors in Australia and New Zealand.

“I’m incredibly excited to be coming back to Streem. Having spent the last few years on the other side of the world, working across the UK and Europe, I can honestly say it has only reinforced how special Streem is. The product truly is the best in the market, and seeing the landscape from the outside has given me an even greater appreciation for what Streem has built, and excited for what’s to come for our customers,” said Tess Fezzuoglio.

“I’m really looking forward to reconnecting with familiar faces and rolling up my sleeves to help drive the next stage of growth alongside such a talented team”.

Senior Vice President for APAC at Cision, Royce Shih, said, “We are thrilled to have Tess re-join Streem, bringing her wealth of international experience, strategic vision, and proven leadership back home to Streem.”

“Her deep understanding of Streem’s roots, combined with the global expertise she has gained, makes her uniquely positioned to guide our commercial teams into our next phase of growth.”

Tess’s appointment is effective immediately.

About Streem

Streem is a leading provider of media intelligence solutions in Australia and New Zealand, empowering organisations to make informed decisions and drive business success through realtime content and insights. Streem is part of Cision, the global leader in PR and marketing communications technology.

For media inquiries, please contact:
Streem 
marketing@streem.com.au

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/streem-welcomes-back-tess-fezzuoglio-as-commercial-director-to-lead-next-phase-of-growth-302886261.html

SOURCE Streem

Continue Reading

Trending